Ensysce Biosciences said this week that its extended-release oxycodone prodrug won fast track status from the FDA. The San Diego, Calif.-based company is developing the abuse-deterrent drug as a pain management therapy for people with moderate to severe chronic pain. Ensysce’s prodrugs are only activated once they reach the small intestine, where enzymes set off […]